Reneo Pharmaceuticals, Inc. (RPHM)
NASDAQ: RPHM · IEX Real-Time Price · USD
1.750
+0.090 (5.42%)
At close: May 17, 2024, 4:00 PM
1.700
-0.050 (-2.86%)
After-hours: May 17, 2024, 7:30 PM EDT
Company Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases.
The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gregory J. Flesher |
Contact Details
Address: 18575 Jamboree Road, Suite 275-s Irvine, California 92612 United States | |
| Phone | (858) 283-0280 |
| Website | reneopharma.com |
Stock Details
| Ticker Symbol | RPHM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001637715 |
| CUSIP Number | 75974E103 |
| ISIN Number | US75974E1038 |
| Employer ID | 47-2309515 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Grey | Founder and Executive Chairman |
| Gregory J. Flesher | President, Chief Executive Officer and Director |
| Michael P. Cruse | Chief Operating Officer |
| Ashley F. Hall J.D. | Chief Development Officer |
| Jennifer P. Lam | SVice President of Finance and Administration and Principal Financial & Accounting Officer |
| Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer |
| Lynn Purkins Ph.D. | Senior Vice President of Global Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | 425 | Filing |
| May 13, 2024 | 8-K | Current Report |
| May 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 8-K | Current Report |